Hot from the press, BMS just received the final pCODR recommendation for Opdivo in lung cancer. PERC has maintained its initial recommendation with no change. This is an excellent news for the patients.
See the information on pCODR website.
Have a great Friday afternoon and a good ASCO Louise!